<DOC>
	<DOCNO>NCT00680498</DOCNO>
	<brief_summary>This one-year , randomize , single-center open-label pilot study safety efficacy combination ranibizumab PDT AMD . Eligible subject randomize either combination treatment , ranibizumab monotherapy ( control group ) . The combination treatment group receive ranibizumab , follow 1 week later verteporfin PDT . Additional treatment base evidence active disease ( subretinal fluid OCT leakage FA ) : repeat ranibizumab injection allow monthly , repeat PDT allow every 3 month . The control group receive `` standard-of-care '' ranibizumab monotherapy accord protocol currently follow retinal specialist . Ranibizumab injection give baseline month one two . Additional injection give monthly visit evidence active disease visual acuity , OCT FA criterion .</brief_summary>
	<brief_title>Combination Lucentis Ocular Photodynamic Therapy With Visudyne , With Evaluation-based Retreatment</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Presence subfoveal CNV due AMD , less 9 disc area extent Vision 20/40 20/800 Snellen equivalent Age &gt; 50 year Ability provide write informed consent comply study assessment full duration study Intraocular surgery injection within 30 day prior enrollment study eye Intravitreal triamcinolone within past 6 month study eye History prior PDT treatment study eye History argon laser treatment subfoveal CNV study eye Other visionlimiting disease ( e.g . advanced glaucoma , prior vascular occlusion , dense amblyopia ) study eye Clinically significant intraocular inflammation study eye No light perception fellow eye Anterior segment opacity prevent adequate visualization fundus FA OCT Are currently participate another clinical trial Women childbearing potential use adequate contraception , well woman breastfeed Known sensitivity study drug ( ) class study drug ( ) Patients severe medical condition ( ) view investigator prohibit participation study Use investigational agent last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>Verteporfin</keyword>
	<keyword>Visudyne</keyword>
</DOC>